Color-enhanced lung cancer cells growing in culture. Image courtesy of Wellcome Images.
The UC San Diego Moores Cancer Center has joined the Worldwide Innovative Network (WIN) Consortium in personalized cancer medicine.
“This linkage with WIN enables UC San Diego to propose and participate in ground-breaking, global clinical trials with leading organizations striving to advance personalized cancer medicine,” said Scott Lippman, MD, director of Moores Cancer Center. “This type of cross-sector collaboration is an important step if we are to quickly bring the benefits of genome-driven discoveries to patients.”
WIN was founded in 2010 by the University of Texas MD Anderson Cancer Center and the Institut Gustave Roussy in France. It’s a global network of 29 universities, patient advocacy groups and companies representing the pharmaceutical, biotechnological and healthcare IT industries, all collaborating to accelerate the pace of translational cancer treatments at lower costs.
“We are thrilled that Moores Cancer Center has become a member of WIN,” said John Mendelsohn, MD, chairman of the WIN Consortium and former president at MD Anderson. “UC San Diego’s outstanding faculty is strongly engaged in collaborative efforts to advance personalized cancer medicine. With its advanced technical capabilities and talented, motivated scientists, the Moores Cancer Center significantly enhances WIN’s ability to bring the latest advances in personalized cancer medicine to patients.”